Adimolol
Chemical compound
- none
- 3-[3-[[2-hydroxy-3-(1-naphthyloxy)propyl]amino]-3-methyl-butyl]-1H-benzimidazol-2-one
- 78459-19-5 N
- 71227
- 64362 Y
- B6CJY5K2ST
- ChEMBL1742448 N
- DTXSID00868480
- Interactive image
- O=C2Nc1ccccc1N2CCC(NCC(O)COc4c3ccccc3ccc4)(C)C
InChI
- InChI=1S/C25H29N3O3/c1-25(2,14-15-28-22-12-6-5-11-21(22)27-24(28)30)26-16-19(29)17-31-23-13-7-9-18-8-3-4-10-20(18)23/h3-13,19,26,29H,14-17H2,1-2H3,(H,27,30) Y
- Key:YWRIUGFSIQMHJK-UHFFFAOYSA-N Y
Adimolol (developmental code name MEN-935) is antihypertensive agent which acts as a non-selective α1-, α2-, and β-adrenergic receptor antagonist.[1]
Synthesis
The reaction between 1-naphthyl glycidyl ether (1) and 3-(3-amino-3-methylbutyl)-1H-benzimidazol-2-one (2) gives adimolol (3).[2][3]
References
- ^ Palluk R, Hoefke W, Gaida W, Mierau J, Bechtel WD (July 1986). "Interactions of MEN 935 (adimolol), a long acting beta- and alpha-adrenolytic antihypertensive agent, with postsynaptic alpha-adrenoceptors in different isolated blood vessels--influence of angiotensin II". Naunyn-Schmiedeberg's Archives of Pharmacology. 333 (3): 277–83. doi:10.1007/bf00512941. PMID 3020439. S2CID 24300936.
- ^ Hoefke W, Gaida W, Palluk R, Mentrup A (1986). "Adimolol Hydrochloride Hydrate". Drugs of the Future. 11: 9. doi:10.1358/dof.1986.011.01.62036.
- ^ US 4255430, Koppe H, Mentrup A, Renth EO, Schromm K, Hoefke W, Muacevic G, issued 1981, assigned to Boehringer Ingelheim Gmbh
- v
- t
- e
(antagonize α-adrenergic
vasoconstriction)
Central |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Peripheral |
|
Serotonin receptor antagonists | |
---|---|
Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This article about an amine is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e